ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Large Growth in Short Interest

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,350,000 shares, a growth of 27.7% from the November 30th total of 1,840,000 shares. Based on an average daily volume of 253,300 shares, the days-to-cover ratio is currently 9.3 days.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,231 shares of company stock worth $2,434,286 in the last ninety days. 12.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares during the last quarter. XTX Topco Ltd acquired a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $207,000. HighTower Advisors LLC bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $222,000. Profund Advisors LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at approximately $225,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $228,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $54.41 on Friday. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -98.93 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company has a 50 day simple moving average of $57.36 and a 200 day simple moving average of $59.56. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same period in the prior year, the business earned $1.05 earnings per share. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. Research analysts anticipate that ANI Pharmaceuticals will post 3.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Raymond James increased their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.